Frank Watanabe, Arcutis CEO
With first drug on the market, Arcutis forks over $16M cash for a buyout
Having scored their first FDA approval, the dermatology specialists at Arcutis have pounced on a new buyout to beef up the pipeline.
Arcutis is acquiring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
